This year looks like a strong one for cancer medication approvals. The chimeric antigen receptor T-cell (CAR-T) therapies are particularly important, according to Ali McBride, PharmD, MS, BCPS, a clinical coordinator in hematology/oncology at the University of Arizona Cancer Center, in Phoenix. Last year, the FDA approved axicabtagene ciloleucel (Yescarta, Kite/Gilead) and tisagenlecleucel (Kymriah, Novartis), and a third CAR-T is expecting approval this year. JCAR017, by Juno Therapeutics,
JANUARY 16, 2018